NUCLEOLIN and cancer: AS1411 is an anti-nucleolin aptamer in phase 2 clinical development with a 26-base guanine-rich oligodeoxynucleotide with potential affinity to nucleolin, a nucleolar phosphoprotein that is overexpressed on the surface of various cancer cells [51,52].